"Targeting the absence" and therapeutic engineering for cancer therapy

Cell Cycle

Volumn 7, Issue 10, 2008, Pages 1307-1312

  Blagosklonny, Mikhail V ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Chemotherapy; Cure; Drug combinations; Drug resistance; Targets

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; BEVACIZUMAB; CISPLATIN; DOXORUBICIN; DOXYCYCLINE; EPOTHILONE A; ETOPOSIDE; FLAVOPIRIDOL; NAVELBINE; PACLITAXEL; PIFITHRIN ALPHA; PROTEIN P53; RAPAMYCIN; VINBLASTINE;

BACTERIOLYSIS; BIOMEDICAL ENGINEERING; CANCER RESISTANCE; CANCER THERAPY; CELL CYCLE ARREST; CYTOTOXICITY; DNA MICROARRAY; DRUG TARGETING; HUMAN; REVIEW;

EID: 45749117120     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.10.6250     Document Type: Review

References (59)

1. Varshavsky A. Targeting the absence: homozygous DNA deletions as immutable signposts for cancer therapy. Proc Natl Acad Sci USA 2007; 104:14935-40.
2. Varshavsky A. Codominant interference, antieffectors, and multitarget drugs. Proc Natl Acad Sci USA 1998; 95:2094-9.
3. Folkman. Angiogenesis inhibitors: A new class of drugs. Cancer Biol Ther 2003; 2:127-33.
4. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998; 16:3158-68.
5. Jain R. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-9.
6. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285:1733-7.
7. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-99.
8. Wei MQ, Ellem KA, Dunn P, West MJ, Bai CX, Vogelstein B. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer 2007; 43:490-6.
9. Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000; 60:6259-65.
10. Arteaga CL. Inhibiting tyrosine kinases: successes and limitations. Cancer Biol Ther 2003; 2:79-83.
11. Primiano T, Baig M, Maliyekkel A, Chang BD, Fellars S, Sadhu J, Axenovich SA, Holzmayer TA, Roninson IB. Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell 2003; 4:41-53.
12. Rowinsky EK. Signal events: Cell signal transduction and its inhibition in cancer. Oncologist 2003; 8:5-17.
13. Li Y, Sun X, LaMont JT, Pardee AB, Li CJ. Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA 2003; 100:2674-8.
14. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004; 206:149-57.
15. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-7.
16. Settleman J. Inhibition of mutant EGF receptors by Gefitinib: Targeting an Achilles' heel of lung cancer. Cell Cycle 2004; 3:1496-7.
17. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432:316-23.
18. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91:1-30.
19. Sawyers C. Targeted cancer therapy. Nature 2004; 432:294-7.
20. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4:423-36.
21. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA. 2005; 102:17448-53.
22. Stein WD, Bates SE, Fojo T. Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr Drug Targets 2004; 5:333-46.
23. Sengupta S, Eavarone D, Capila I, Zhao GL, Watson N, Kiziltepe T, Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005; 436:568-72.
24. Goldsmith ME, Aguila A, Steadman K, Martinez A, Steinberg SM, Alley MC, Waud WR, Bates SE, Fojo T. The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Mol Cancer Ther 2007; 6:496-505.
25. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7:684-700.
26. Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 2000; 105:533-9.
27. Demidenko ZN, Halicka D, Kunicki J, McCubrey JA, Darzynkiewicz Z, Blagosklonny MV. Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. Cancer Res 2005; 65:4401-7.
28. Blagosklonny MV. A new science-business paradigm in anticancer drug development. Trends Biotechnol 2003; 21:103-6.
29. Blagosklonny MV. Overcoming limitations of natural anticancer drugs by combining with designed agents. Trends Pharm Sci 2005; 26:77-81
30. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005; 65:1918-24.
31. Blagosklonny MV. Antagonistic Drug Combinations That Select Against Drug Resistance: From Bacteria to Cancer. Cancer Biol Ther 2007; 6:1013-4.
32. Takimoto CH, Rowinsky EK. Dose-intense paclitaxel: deja vu all over again? J Clin Oncol 2003; 21:2810-4.
33. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357:340-8.
34. Blagosklonny MV. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 2002; 21:6249-54.
35. Blagosklonny MV. Matching targets for selective cancer therapy. Drug Discov Today. 2003; 8:1104-7.
36. Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia 2001;15:936-41.
37. Blagosklonny MV. Tissue-selective therapy of cancer. Br J Cancer 2003; 89:1147-51.
38. Blagosklonny MV. Drug-resistance enables selective killing of resistant leukemia cells: exploiting ofdrug resistance instead of reversal. Leukemia 1999; 13:2031-5.
39. Blagosklonny MV. Targeting cancer cells by exploiting their resistance. Trends Mol Med 2003; 9:307-12.
40. Blagosklonny MV. Carcinogenesis, cancer therapy and chemoprevention. Cell Death Differ 2005; 12:592-602.
41. Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy. Int J Oncol 2001; 19:257-62.
42. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:3706-12.
43. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
44. Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nature Rev Cancer 2002; 2:221-5.
45. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 2005; 4:1693-8.
46. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004; 64:3653-60.
47. Blagosklonny MV. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 2007; 6:70-4.
48. Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, Schmoll HJ. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res 2003; 63:513-21.
49. Blagosklonny MV. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle 2004; 3:1035-42.
50. Blagosklonny MV. How Cancer Could Be Cured by 2015. Cell Cycle 2005; 4:269-78.
51. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001; 98:15155-60.
52. Dang LH, Bettegowda C, Agrawal N, Cheong I, Huso D, Frost P, Loganzo F, Greenberger L, Barkoczy J, Pettit GR, Smith ABr, Gurulingappa H, Khan S, Parmigiani G, Kinzler KW, Zhou S, Vogelstein B. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 2004; 3:326-37.
53. Cheong I, Huang X, Bettegowda C, Diaz LAJ, Kinzler KW, Zhou S, Vogelstein B. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 2006; 314:1308-11.
54. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, Kurnasov OV, Fort FL, Osterman AL, Didonato JA, Feinstein E, Gudkov AV. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008; 320:226-30.
55. Komarova EA, Gudkov AV. Could p53 be a target for therapeutic suppression? Semin Cancer Biol 1998; 8:389-400.
56. Botchkarev VA, Komarova EA, Siebenhaar F, Botchkareva NV, Komarov PG, Maurer M, Gilchrest BA, Gudkov AV. p53 is essential for chemotherapy-induced hair loss. Cancer Res 2000; 60:5002-6.
57. Komarova EA, Gudkov AV. Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors. Biochem Pharmacol 2001; 62:657-67.
58. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, Komarova EA, Gudkov AV. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006; 2:474-9.
59. Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today 2007; 12:218-24.